{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T03:28:52Z","timestamp":1772594932972,"version":"3.50.1"},"reference-count":21,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1016\/j.bbrc.2014.02.045","type":"journal-article","created":{"date-parts":[[2014,2,21]],"date-time":"2014-02-21T22:46:15Z","timestamp":1393022775000},"page":"511-516","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["A novel exendin-4 human serum albumin fusion protein, E2HSA, with an extended half-life and good glucoregulatory effect in healthy rhesus monkeys"],"prefix":"10.1016","volume":"445","author":[{"given":"Ling","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiyun","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Gan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruolan","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuona","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoxia","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenzhong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guifang","family":"Dou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2014.02.045_b0005","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.2337\/diabetes.53.9.2181","article-title":"Therapeutic strategies based on glucagon-like peptide 1","volume":"53","author":"Deacon","year":"2004","journal-title":"Diabetes"},{"key":"10.1016\/j.bbrc.2014.02.045_b0010","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","article-title":"Biology of incretins: GLP-1 and GIP","volume":"132","author":"Baggio","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bbrc.2014.02.045_b0015","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.mce.2008.08.012","article-title":"The incretin system and its role in type 2 diabetes","volume":"297","author":"Holst","year":"2009","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.bbrc.2014.02.045_b0020","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1111\/j.1432-1033.1993.tb17986.x","article-title":"Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7\u201336) amide, peptide histidine methionine and is responsible for their degradation in human serum","volume":"214","author":"Mentlein","year":"1993","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.bbrc.2014.02.045_b0025","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1210\/endo.136.8.7628397","article-title":"Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV","volume":"136","author":"Kieffer","year":"1995","journal-title":"Endocrinology"},{"key":"10.1016\/j.bbrc.2014.02.045_b0030","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jconrel.2010.01.024","article-title":"The fatty acid conjugated exendin-4 analogs for type 2 antidiabetic therapeutics","volume":"144","author":"Chae","year":"2010","journal-title":"J. Control Release"},{"key":"10.1016\/j.bbrc.2014.02.045_b0035","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.jconrel.2009.10.025","article-title":"Biochemical, pharmaceutical and therapeutic properties of long-acting lithocholic acid derivatized exendin-4 analogs","volume":"142","author":"Chae","year":"2010","journal-title":"J. Control Release."},{"key":"10.1016\/j.bbrc.2014.02.045_b0040","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jconrel.2008.09.091","article-title":"A new orally available glucagon-like peptide-1 receptor agonist, biotinylated exendin-4, displays improved hypoglycemic effects in db\/db mice","volume":"133","author":"Jin","year":"2009","journal-title":"J. Control Release"},{"key":"10.1016\/j.bbrc.2014.02.045_b0045","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1271\/bbb.80742","article-title":"Development, characterization, and evaluation of a fusion protein of a novel glucagon-like peptide-1 (GLP-1) analog and human serum albumin in Pichia pastoris","volume":"73","author":"Gao","year":"2009","journal-title":"Biosci. Biotechnol. Biochem."},{"key":"10.1016\/j.bbrc.2014.02.045_b0050","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1152\/ajpendo.1979.237.3.E214","article-title":"Glucose clamp technique: a method for quantifying insulin secretion and resistance","volume":"237","author":"DeFronzo","year":"1979","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.bbrc.2014.02.045_b0055","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/dmrr.538","article-title":"Glucagon-like peptide 1 (GLP-1) in biology and pathology","volume":"21","author":"Meier","year":"2005","journal-title":"Diabetes Metab. Res. Rev."},{"key":"10.1016\/j.bbrc.2014.02.045_b0060","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1172\/JCI30076","article-title":"The role of gut hormones in glucose homeostasis","volume":"117","author":"Drucker","year":"2007","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bbrc.2014.02.045_b0065","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","article-title":"The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes","volume":"368","author":"Drucker","year":"2006","journal-title":"The Lancet"},{"key":"10.1016\/j.bbrc.2014.02.045_b0070","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/j.1463-1326.2008.00992.x","article-title":"Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects","volume":"11","author":"Bush","year":"2009","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.bbrc.2014.02.045_b0075","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.2337\/dc09-0366","article-title":"Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes","volume":"32","author":"Rosenstock","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.bbrc.2014.02.045_b0080","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1023\/A:1015396825274","article-title":"Pharmaceutical strategies utilizing recombinant human serum albumin","volume":"19","author":"Chuang","year":"2002","journal-title":"Pharm. Res."},{"key":"10.1016\/j.bbrc.2014.02.045_b0085","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/00006676-199610000-00010","article-title":"Ligand-induced regulation of glucogan-like peptide receptor function and expression in insulin-secreting beta cells","volume":"13","author":"Fehmann","year":"1996","journal-title":"Pancreas"},{"key":"10.1016\/j.bbrc.2014.02.045_b0090","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1124\/pr.55.1.6","article-title":"Glucogan receptor family","volume":"55","author":"Mayo","year":"2003","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.bbrc.2014.02.045_b0095","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S1359-6446(05)03575-0","article-title":"PEGylation, successful approach to drug delivery","volume":"10","author":"Veronese","year":"2005","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.bbrc.2014.02.045_b0100","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/ddr.1195","article-title":"Pharmacokinetic action of exendin-4 in the rat: comparison with glucogan-like peptide-1","volume":"53","author":"Parkes","year":"2001","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.bbrc.2014.02.045_b0105","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1152\/ajpregu.00323.2007","article-title":"The GLP-1 agonist exendin-4 reduces food intake in nonhuman primates through changes in meal size","volume":"293","author":"Scott","year":"2007","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X14003076?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X14003076?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T21:36:06Z","timestamp":1565213766000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X14003076"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["S0006291X14003076"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2014.02.045","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A novel exendin-4 human serum albumin fusion protein, E2HSA, with an extended half-life and good glucoregulatory effect in healthy rhesus monkeys","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2014.02.045","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}